Chapter 12 – Pharmacologic Management of Heart Failure in the Ambulatory Setting

[1]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[2]  M. Walsh,et al.  Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. , 2012, Journal of cardiac failure.

[3]  K. Dickstein,et al.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE , 2012, European journal of heart failure.

[4]  J. Coresh,et al.  Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. , 2012, Arthritis and rheumatism.

[5]  D. Atar,et al.  Dronedarone in high-risk permanent atrial fibrillation. , 2011, The New England journal of medicine.

[6]  Akshay S. Desai,et al.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. , 2011, American heart journal.

[7]  K. Swedberg,et al.  Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. , 2011, European Heart Journal.

[8]  J. Cleland,et al.  Limited role for ivabradine in the treatment of chronic heart failure , 2011, Heart.

[9]  K. Mcintyre,et al.  Noninvasive monitoring of left ventricular end-diastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial. , 2011, Journal of cardiac failure.

[10]  M. Packer.  Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. , 2011, Circulation. Heart failure.

[11]  C. O'connor,et al.  Influence of global region on outcomes in heart failure β-blocker trials. , 2011, Journal of the American College of Cardiology.

[12]  C. Lang,et al.  Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. , 2011, Journal of the American College of Cardiology.

[13]  P. Stone.  Allopurinol a new anti-ischemic role for an old drug. , 2011, Journal of the American College of Cardiology.

[14]  C. Brensinger,et al.  Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. , 2011, Journal of the American College of Cardiology.

[15]  R. Bonow.  Surgical ventricular reconstruction for heart failure: is there life after STICH? , 2011, JACC. Cardiovascular imaging.

[16]  J. Towbin,et al.  Effectiveness of mechanical circulatory support in children with acute fulminant and persistent myocarditis. , 2011, Journal of cardiac failure.

[17]  G. Lip,et al.  Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. , 2011, Journal of the American College of Cardiology.

[18]  C. Yancy,et al.  Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspective, Mechanisms, and Future Directions , 2011, Circulation.

[19]  A. Nègre-Salvayre,et al.  Antiatherogenic effect of bisvanillyl-hydralazone, a new hydralazine derivative with antioxidant, carbonyl scavenger, and antiapoptotic properties. , 2011, Antioxidants & redox signaling.

[20]  A. Pavie,et al.  Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support* , 2011, Critical care medicine.

[21]  J. Fang.  Underestimating medical therapy for coronary disease... again. , 2011, The New England journal of medicine.

[22]  C. O'connor,et al.  Coronary-artery bypass surgery in patients with left ventricular dysfunction. , 2011, The New England journal of medicine.

[23]  D. Berman,et al.  Myocardial viability and survival in ischemic left ventricular dysfunction. , 2011, The New England journal of medicine.

[24]  Saibal Kar,et al.  Percutaneous repair or surgery for mitral regurgitation. , 2011, The New England journal of medicine.

[25]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[26]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[27]  E. Lewis.  End of Life Care in Advanced Heart Failure , 2011, Current treatment options in cardiovascular medicine.

[28]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[29]  R. Arena,et al.  Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.

[30]  Ayan R Patel,et al.  Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. , 2011, JACC. Cardiovascular imaging.

[31]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[32]  M. Shuster,et al.  Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. , 2010, Circulation.

[33]  Adrian F. Hernandez,et al.  Combination of loop diuretics with thiazide-type diuretics in heart failure. , 2010, Journal of the American College of Cardiology.

[34]  J. Teerlink.  Ivabradine in heart failure—no paradigm SHIFT…yet , 2010, The Lancet.

[35]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[36]  J. Burnett,et al.  CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease , 2010, Current heart failure reports.

[37]  C. Lang,et al.  Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial , 2010, The Lancet.

[38]  M. Guglin,et al.  Pulmonary hypertension in heart failure. , 2010, Journal of cardiac failure.

[39]  Nancy M Albert,et al.  HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.

[40]  T. Fahey,et al.  Spironolactone use and renal toxicity: population based longitudinal analysis , 2010, BMJ : British Medical Journal.

[41]  E. Benjamin,et al.  Atrial fibrillation in congestive heart failure. , 2010, Heart failure clinics.

[42]  A. Frustaci.  Cytopathic pathways of enteroviral myocardial infection. , 2010, European heart journal.

[43]  Akshay S. Desai,et al.  The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. , 2010, Journal of cardiac failure.

[44]  P. Deedwania,et al.  Atrial fibrillation in heart failure: a comprehensive review. , 2010, The American journal of medicine.

[45]  L. Lazzeroni,et al.  An &agr;2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the &bgr;-Blocker Bucindolol in Chronic Heart Failure , 2010, Circulation. Heart failure.

[46]  C. Yancy,et al.  Treatment of heart failure in African Americans: a consensus statement. , 2010, Congestive heart failure.

[47]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[48]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[49]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[50]  Akshay S. Desai,et al.  Hyperkalemia in patients with heart failure: Incidence, prevalence, and management , 2009, Current heart failure reports.

[51]  R. Shah,et al.  Managing acute renal failure in patients with acute decompensated heart failure: The cardiorenal syndrome , 2009, Current heart failure reports.

[52]  S. Solomon,et al.  Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial , 2009, European journal of heart failure.

[53]  Andrea Frustaci,et al.  Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. , 2009, European heart journal.

[54]  C. O'connor,et al.  Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial , 2009, Circulation.

[55]  M. Gorostidi,et al.  Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren: A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide , 2009, Circulation.

[56]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[57]  Stefano Ghio,et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.

[58]  K. Bailey,et al.  Usefulness of immunosuppression for giant cell myocarditis. , 2008, The American journal of cardiology.

[59]  Rinaldo Bellomo,et al.  Cardiorenal syndrome. , 2008, Journal of the American College of Cardiology.

[60]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[61]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[62]  Joanne Brown,et al.  Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. , 2008, Journal of the American College of Cardiology.

[63]  S. Solomon,et al.  Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.

[64]  R. Arena,et al.  Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.

[65]  Renu Virmani,et al.  A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology , 2022 .

[66]  R. Gerszten,et al.  Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .

[67]  R. Nesto,et al.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.

[68]  A. Tahrani,et al.  Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? , 2007, BMJ : British Medical Journal.

[69]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[70]  K. McDonald,et al.  Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. , 2007, Journal of cardiac failure.

[71]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[72]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[73]  G. Lewis,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[74]  L. Cooper,et al.  Noninvasive imaging in myocarditis. , 2006, Journal of the American College of Cardiology.

[75]  N. Freemantle,et al.  FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .

[76]  A. Feldman,et al.  Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. , 2006, Journal of the American College of Cardiology.

[77]  L. Lazzeroni,et al.  A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure , 2006 .

[78]  Jared W. Magnani,et al.  Myocarditis: Current Trends in Diagnosis and Treatment , 2006, Circulation.

[79]  E. Fain,et al.  Comparison of (cid:1) -Blockers, Amiodarone Plus (cid:1) -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators The OPTIC Study: A Randomized Trial , 2005 .

[80]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[81]  T. Münzel,et al.  Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. , 2005, Biochemical and biophysical research communications.

[82]  T. Malinski,et al.  Nebivolol Reduces Nitroxidative Stress and Restores Nitric Oxide Bioavailability in Endothelium of Black Americans , 2005, Circulation.

[83]  D. Morrow,et al.  Modulation of Myocardial Energetics: Emerging Evidence for a Therapeutic Target in Cardiovascular Disease , 2005, Circulation.

[84]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[85]  M. Gheorghiade,et al.  Vasopressin antagonism in heart failure. , 2005, Journal of the American College of Cardiology.

[86]  R. Hendel,et al.  A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. , 2005, Journal of the American College of Cardiology.

[87]  William T. Abraham,et al.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness , 2005 .

[88]  W. Stevenson,et al.  Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. , 2005, American heart journal.

[89]  S. Gottlieb,et al.  The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. , 2005, Journal of the American College of Cardiology.

[90]  C. Lau,et al.  Intrathoracic Impedance Monitoring in Patients With Heart Failure: Correlation With Fluid Status and Feasibility of Early Warning Preceding Hospitalization , 2005, Circulation.

[91]  J. Soler‐Soler,et al.  Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction , 2005, European journal of heart failure.

[92]  N. Markandu,et al.  Modest Salt Reduction Reduces Blood Pressure and Urine Protein Excretion in Black Hypertensives: A Randomized Control Trial , 2005, Hypertension.

[93]  K. Adams,et al.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.

[94]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005, American heart journal.

[95]  S. Bolling,et al.  Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. , 2005, Journal of the American College of Cardiology.

[96]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[97]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[98]  Stuart D Katz,et al.  Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure , 2005, Circulation.

[99]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[100]  C. O'connor,et al.  Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. , 2004, Journal of the American College of Cardiology.

[101]  Hao Wang,et al.  Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. , 2005, The American journal of cardiology.

[102]  W. Stevenson,et al.  Atrial fibrillation and heart failure--five more years. , 2004, The New England journal of medicine.

[103]  U. Elkayam,et al.  Survey of the use of organic nitrates for the treatment of chronic congestive heart failure in the United States. , 2004, The American journal of cardiology.

[104]  J. Hare.  Nitroso-redox balance in the cardiovascular system. , 2004, The New England journal of medicine.

[105]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[106]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[107]  J. Mustonen,et al.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.

[108]  A. Tejeda,et al.  Effects of a nutritional intervention on body composition, clinical status, and quality of life in patients with heart failure. , 2004 .

[109]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[110]  P A Poole-Wilson,et al.  The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. , 2004, American heart journal.

[111]  M. Gheorghiade,et al.  Digoxin in the management of cardiovascular disorders. , 2004, Circulation.

[112]  D. Mancini,et al.  Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. , 2004, The American journal of cardiology.

[113]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[114]  V. Hasselblad,et al.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.

[115]  C. O'connor,et al.  Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial , 2004 .

[116]  C. O'connor,et al.  The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. , 2004, Journal of cardiac failure.

[117]  S. Katz,et al.  Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[118]  M. Fishbein,et al.  Eosinophilic myocarditis in patients awaiting heart transplantation* , 2004, Critical care medicine.

[119]  B. Chaitman,et al.  Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. , 2004, JAMA.

[120]  A. López-Candales,et al.  Need for hospice and palliative care services in patients with end‐stage heart failure treated with intermittent infusion of inotropes , 2004, Clinical cardiology.

[121]  S. Grundy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association , 2003, Diabetes care.

[122]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[123]  D. Kaye,et al.  Feasibility and Short-Term Efficacy of Percutaneous Mitral Annular Reduction for the Therapy of Heart Failure-Induced Mitral Regurgitation , 2003, Circulation.

[124]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[125]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[126]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[127]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[128]  J. Rouleau,et al.  Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. , 2003, American heart journal.

[129]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[130]  H. Krumholz,et al.  Metformin and thiazolidinedione use in Medicare patients with heart failure. , 2003, JAMA.

[131]  M. Rich.  Drug therapy of heart failure in the elderly. , 2003, The American journal of geriatric cardiology.

[132]  James Fang,et al.  Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. , 2003, Journal of the American College of Cardiology.

[133]  R. Hershberger,et al.  Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. , 2003, Journal of cardiac failure.

[134]  C. O'connor,et al.  Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? , 2003, American heart journal.

[135]  Paul G Shekelle,et al.  Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.

[136]  B. Hoogwerf,et al.  Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. , 2003, Journal of the American College of Cardiology.

[137]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[138]  C. Lang,et al.  Morbidity and mortality of UNOS status 1B cardiac transplant candidates at home. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[139]  E. Havranek,et al.  Age, but not sex, influences the measurement of ejection fraction in elderly patients hospitalized for heart failure. , 2003, Journal of cardiac failure.

[140]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[141]  Harlan M Krumholz,et al.  Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.

[142]  G. Thiene,et al.  Immunosuppressive Therapy for Active Lymphocytic Myocarditis: Virological and Immunologic Profile of Responders Versus Nonresponders , 2003, Circulation.

[143]  C. Lang,et al.  Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure , 2003, Circulation.

[144]  J. Steiner,et al.  Gender, age, and heart failure with preserved left ventricular systolic function. , 2003, Journal of the American College of Cardiology.

[145]  B. Bozkurt,et al.  Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. , 2003, Journal of the American College of Cardiology.

[146]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[147]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[148]  Harlan M Krumholz,et al.  Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.

[149]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[150]  R. Collins,et al.  Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review , 2002, The Lancet.

[151]  B. Fagerberg,et al.  Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). , 2002, Journal of the American College of Cardiology.

[152]  J. Loscalzo,et al.  Effects of Black Race on Forearm Resistance Vessel Function , 2002, Hypertension.

[153]  G. Fonarow,et al.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. , 2002, Journal of the American College of Cardiology.

[154]  S. Archer,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension Comparison With Inhaled Nitric Oxide , 2002 .

[155]  I. Piña,et al.  Metoprolol CR/XL in Female Patients With Heart Failure: Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) , 2002, Circulation.

[156]  D. Brutsaert,et al.  New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. , 2002, Circulation.

[157]  D. Brutsaert,et al.  New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. , 2002, Circulation.

[158]  H. Krumholz,et al.  β-Blocker Therapy in Heart Failure: Scientific Review , 2002 .

[159]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[160]  W. Stevenson,et al.  Management of arrhythmias in heart failure. , 1993, Cardiology in review.

[161]  M. Drazner,et al.  Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure. , 2002, American heart journal.

[162]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[163]  K. Weber.  Aldosterone in congestive heart failure. , 2001, The New England journal of medicine.

[164]  J. Ghali,et al.  Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .

[165]  M. Senni,et al.  Heart failure with preserved systolic function. A different natural history? , 2001, Journal of the American College of Cardiology.

[166]  M. Givertz.  Manipulation of the renin-angiotensin system. , 2001, Circulation.

[167]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[168]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[169]  R. Holubkov,et al.  Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy , 2001, Circulation.

[170]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[171]  C. Yancy,et al.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. , 2001, The New England journal of medicine.

[172]  E. Philbin,et al.  Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. , 2000, The American journal of medicine.

[173]  W. Colucci,et al.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. , 2000, Circulation.

[174]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[175]  M. Drazner,et al.  Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[176]  L. Mendes,et al.  Noninvasive methods for detecting elevated left-sided cardiac filling pressure. , 2000, Journal of cardiac failure.

[177]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[178]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[179]  R. Hruban,et al.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. , 2000, The New England journal of medicine.

[180]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[181]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[182]  D. V. van Veldhuisen,et al.  Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. , 2000, American heart journal.

[183]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[184]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[185]  O. Frazier,et al.  Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. , 1999, The New England journal of medicine.

[186]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[187]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[188]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[189]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[190]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[191]  D. Bello,et al.  Self-reported differences between cardiologists and heart failure specialists in the management of chronic heart failure. , 1999, American heart journal.

[192]  P. Armstrong,et al.  Insights into the contemporary epidemiology and outpatient management of congestive heart failure. , 1999, American heart journal.

[193]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[194]  D. Levy,et al.  Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. , 1999, Journal of the American College of Cardiology.

[195]  R. Nesto,et al.  The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. , 1999, Journal of the American College of Cardiology.

[196]  D. Mancini,et al.  Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. , 1999, Circulation.

[197]  C. Kawai,et al.  From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. , 1999, Circulation.

[198]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[199]  D. DeMets,et al.  A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure , 1998 .

[200]  P C Deedwania,et al.  Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.

[201]  J. Feenstra,et al.  Angioneurotic edema attributed to the use of losartan. , 1998, Archives of internal medicine.

[202]  M. Pfeffer,et al.  ACE inhibitors in acute myocardial infarction: patient selection and timing. , 1998, Circulation.

[203]  E. Braunwald,et al.  Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. , 1998, Circulation.

[204]  W. Rand,et al.  Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.

[205]  W. Rand,et al.  Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. , 1998, Journal of the American College of Cardiology.

[206]  J. Feinglass,et al.  Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. , 1997, American heart journal.

[207]  Milton Packer,et al.  Safety and efficacy of carvedilol in severe heart failure , 1997 .

[208]  G. Fonarow,et al.  Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. , 1997, Circulation.

[209]  J. Cohn,et al.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. , 1997, Circulation.

[210]  G. Berry,et al.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. , 1997, The New England journal of medicine.

[211]  A. Demetris,et al.  Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. , 1997, Circulation.

[212]  P. Agostoni,et al.  Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. , 1997, Circulation.

[213]  M. Domanski,et al.  Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. , 1997, Journal of the American College of Cardiology.

[214]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[215]  G. Lamas,et al.  Ventricular dysfunction and the risk of stroke after myocardial infarction. , 1997, The New England journal of medicine.

[216]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[217]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[218]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[219]  M. Packer.  Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? , 1996, Journal of the American College of Cardiology.

[220]  S. Bolling,et al.  Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. , 1996, The American journal of cardiology.

[221]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[222]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[223]  M. Pfeffer,et al.  Beta-adrenergic blockers and survival in heart failure. , 1996, The New England journal of medicine.

[224]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[225]  E. Philbin,et al.  Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. , 1996, The American journal of cardiology.

[226]  B. Pitt.  Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). , 1996, The American journal of cardiology.

[227]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[228]  T. Yue,et al.  Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. , 1995, Pharmacology.

[229]  B. McManus,et al.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. , 1995, The New England journal of medicine.

[230]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[231]  B Bornkessel,et al.  [Angiotensin II receptor antagonists]. , 1995, Medizinische Monatsschrift fur Pharmazeuten.

[232]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[233]  P. Grayburn,et al.  Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.

[234]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[235]  K. Dickstein,et al.  Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. , 1995, Circulation.

[236]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[237]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[238]  S. Hohnloser,et al.  Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.

[239]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[240]  M. Gheorghiade,et al.  WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS , 2010 .

[241]  J. Brouwer,et al.  Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). , 1993, Journal of the American College of Cardiology.

[242]  B. Uretsky,et al.  Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. , 1993, Journal of the American College of Cardiology.

[243]  M. Condorelli,et al.  Abnormalities of Sodium Handling and of Cardiovascular Adaptations During High Salt Diet in Patients With Mild Heart Failure , 1993, Circulation.

[244]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[245]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.

[246]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[247]  R. Cooper,et al.  Survival of heart failure patients with preserved versus impaired systolic function: the prognostic implication of blood pressure. , 1992, American heart journal.

[248]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[249]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[250]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[251]  D. Ellison.  The physiologic basis of diuretic synergism: its role in treating diuretic resistance. , 1991, Annals of internal medicine.

[252]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[253]  K. Swedberg,et al.  Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. , 1990, The American journal of cardiology.

[254]  H. Herrmann,et al.  Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. , 1990, Circulation.

[255]  S. Gottlieb,et al.  Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. , 1990, Circulation.

[256]  W. Stevenson,et al.  Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. , 1989, Circulation.

[257]  R. Schlant,et al.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. , 1989, The New England journal of medicine.

[258]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.

[259]  F. S. Wright,et al.  Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. , 1989, The Journal of clinical investigation.

[260]  J. Stratton,et al.  Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. , 1988, Circulation.

[261]  M. Wilén,et al.  Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. , 1988, JAMA.

[262]  B. McManus,et al.  Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. , 1987, The American journal of cardiology.

[263]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[264]  R. Cody,et al.  Sodium and water balance in chronic congestive heart failure. , 1986, The Journal of clinical investigation.

[265]  E. Braunwald,et al.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. , 1986, The New England journal of medicine.

[266]  Michael V. Green,et al.  Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. , 1985, Circulation.

[267]  J. Cohn,et al.  Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. , 1985, Annals of internal medicine.

[268]  B. Massie,et al.  Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. , 1985, Circulation.

[269]  M. Packer,et al.  Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. , 1984, Journal of the American College of Cardiology.

[270]  J. Laragh,et al.  Use of captopril to estimate renin-angiotensin-aldosterone activity in the pathophysiology of chronic heart failure. , 1982, American heart journal.

[271]  A. Moss,et al.  Digitalis‐associated Cardiac Mortality After Myocardial Infarction , 1981, Circulation.

[272]  V. Fuster,et al.  The natural history of idiopathic dilated cardiomyopathy. , 1981, The American journal of cardiology.

[273]  J. Cohn,et al.  Vasodilator Therapy of Cardiac Failure , 1977 .

[274]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.